Use of biologics in severe food allergies

Alessandro Fiocchi, Valentina Pecora, Rocco L. Valluzzi, Vincenzo Fierro, Maurizio Mennini

Research output: Contribution to journalReview articlepeer-review


Purpose of review: Severe cases of food allergy account for the majority of the burden in terms of risks, quality of life, and resource expenditure. The traditional approach to these forms has been strict avoidance. More recently, Oral ImmunoTherapy (OIT) has gained a role in their management. However, in severe food allergies OIT is often infeasible. Recent findings: Case reports, observational, and prospective studies have recently proposed different approaches to severe food allergy. The majority of them include the use of biologics. Omalizumab has been the most studied drug for severe food allergies, and its role as adjuvant treatment to OIT is well established. Interest has been raised on other biologics, as dupilumab, reslizumab, and mepolizumab. Toll-like receptor agonists, and gene therapy using adeno-associated virus coding for Omalizumab are promising alternatives. Summary: The recent studies are deeply influencing the clinical practice. We review the modifications of the clinical approach to severe food allergies so far available. We indicate the possible evolutions of treatment with biologics in severe food allergies.

Original languageEnglish
Pages (from-to)232-238
Number of pages7
JournalCurrent Opinion in Allergy and Clinical Immunology
Issue number3
Publication statusPublished - Jan 1 2017


  • Dupilumab
  • Food allergy
  • Omalizumab
  • Severe food allergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Use of biologics in severe food allergies'. Together they form a unique fingerprint.

Cite this